IL-1 inhibitors linked to ‘significant reduction’ in COVID-19 mortality

Interleukin-1 inhibitors are associated with a “significant reduction” in mortality among patients hospitalized with COVID-19, respiratory insufficiency and hyperinflammation, according to data published in The Lancet Rheumatology.However, this association was not found with IL-6 inhibition, which was only effective in patients with “markedly high” C-reactive protein

Read the full article here

Related Articles